title: Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data.
abstract: BACKGROUND
  The meta-Analysis of Cell-based CaRdiac study is the first prospectively declared collaborative multinational database, including individual data of patients with ischemic heart disease treated with cell therapy.
  
  
  OBJECTIVE
  We analyzed the safety and efficacy of intracoronary cell therapy after acute myocardial infarction (AMI), including individual patient data from 12 randomized trials (ASTAMI, Aalst, BOOST, BONAMI, CADUCEUS, FINCELL, REGENT, REPAIR-AMI, SCAMI, SWISS-AMI, TIME, LATE-TIME; n=1252).
  
  
  RESULTS
  The primary end point was freedom from combined major adverse cardiac and cerebrovascular events (including all-cause death, AMI recurrance, stroke, and target vessel revascularization). The secondary end point was freedom from hard clinical end points (death, AMI recurrence, or stroke), assessed with random-effects meta-analyses and Cox regressions for interactions. Secondary efficacy end points included changes in end-diastolic volume, end-systolic volume, and ejection fraction, analyzed with random-effects meta-analyses and ANCOVA. We reported weighted mean differences between cell therapy and control groups. No effect of cell therapy on major adverse cardiac and cerebrovascular events (14.0% versus 16.3%; hazard ratio, 0.86; 95% confidence interval, 0.63-1.18) or death (1.4% versus 2.1%) or death/AMI recurrence/stroke (2.9% versus 4.7%) was identified in comparison with controls. No changes in ejection fraction (mean difference: 0.96%; 95% confidence interval, -0.2 to 2.1), end-diastolic volume, or systolic volume were observed compared with controls. These results were not influenced by anterior AMI location, reduced baseline ejection fraction, or the use of MRI for assessing left ventricular parameters.
  
  
  CONCLUSIONS
  This meta-analysis of individual patient data from randomized trials in patients with recent AMI revealed that intracoronary cell therapy provided no benefit, in terms of clinical events or changes in left ventricular function.
  
  
  BACKGROUND
  URL: http://www.clinicaltrials.gov. Unique identifier: NCT01098591.
authors.forename: Mariann
authors.initials: M
authors.lastname: Gyöngyösi
authors.forename: Wojciech
authors.initials: W
authors.lastname: Wojakowski
authors.forename: Patricia
authors.initials: P
authors.lastname: Lemarchand
authors.forename: Ketil
authors.initials: K
authors.lastname: Lunde
authors.forename: Michal
authors.initials: M
authors.lastname: Tendera
authors.forename: Jozef
authors.initials: J
authors.lastname: Bartunek
authors.forename: Eduardo
authors.initials: E
authors.lastname: Marban
authors.forename: Birgit
authors.initials: B
authors.lastname: Assmus
authors.forename: Timothy D
authors.initials: TD
authors.lastname: Henry
authors.forename: Jay H
authors.initials: JH
authors.lastname: Traverse
authors.forename: Lemuel A
authors.initials: LA
authors.lastname: Moyé
authors.forename: Daniel
authors.initials: D
authors.lastname: Sürder
authors.forename: Roberto
authors.initials: R
authors.lastname: Corti
authors.forename: Heikki
authors.initials: H
authors.lastname: Huikuri
authors.forename: Johanna
authors.initials: J
authors.lastname: Miettinen
authors.forename: Jochen
authors.initials: J
authors.lastname: Wöhrle
authors.forename: Slobodan
authors.initials: S
authors.lastname: Obradovic
authors.forename: Jérome
authors.initials: J
authors.lastname: Roncalli
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Malliaras
authors.forename: Evgeny
authors.initials: E
authors.lastname: Pokushalov
authors.forename: Alexander
authors.initials: A
authors.lastname: Romanov
authors.forename: Jens
authors.initials: J
authors.lastname: Kastrup
authors.forename: Martin W
authors.initials: MW
authors.lastname: Bergmann
authors.forename: Douwe E
authors.initials: DE
authors.lastname: Atsma
authors.forename: Axel
authors.initials: A
authors.lastname: Diederichsen
authors.forename: Istvan
authors.initials: I
authors.lastname: Edes
authors.forename: Imre
authors.initials: I
authors.lastname: Benedek
authors.forename: Theodora
authors.initials: T
authors.lastname: Benedek
authors.forename: Hristo
authors.initials: H
authors.lastname: Pejkov
authors.forename: Noemi
authors.initials: N
authors.lastname: Nyolczas
authors.forename: Noemi
authors.initials: N
authors.lastname: Pavo
authors.forename: Jutta
authors.initials: J
authors.lastname: Bergler-Klein
authors.forename: Imre J
authors.initials: IJ
authors.lastname: Pavo
authors.forename: Christer
authors.initials: C
authors.lastname: Sylven
authors.forename: Sergio
authors.initials: S
authors.lastname: Berti
authors.forename: Eliano P
authors.initials: EP
authors.lastname: Navarese
authors.forename: Gerald
authors.initials: G
authors.lastname: Maurer
mesh_terms: D000368:Aged; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000401:mortality; D002561:Cerebrovascular Disorders / Q000209:etiology / Q000401:mortality; D016009:Chi-Square Distribution; D016208:Databases, Factual; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000401:mortality / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D009206:Myocardium / Q000473:pathology*; D016016:Proportional Hazards Models; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D020127:Recovery of Function; D012008:Recurrence; D012038:Regeneration; D012307:Risk Factors; D013318:Stroke Volume; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left; D020257:Ventricular Remodeling
keywords: anterior wall myocardial infarction; heart failure; meta-analysis; outcome assessment; stem cells